ClinicalTrials.gg
TerminatedNCT00634088Updated Mar 10, 2016Results posted

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

A Phase 1 interventional study of Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg and Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg in Locally Advanced or Metastatic Breast Cancer, sponsored by R-Pharm. Terminated at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.

Sponsored by R-Pharm · Phase 1, Interventional, and Treatment

Why this study was terminated
Slow Accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.

Enrollment
34th of 39
13 · median 56
Started
2008
with 10 others
Phase 1
7 of 41
none open now
Registered
18th of 41
by date
Lead sponsor
13 of 41
R-Pharm

Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2008, is one of 7 in phase 1, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About ixabepilone

ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing ixabepilone in Breast Neoplasms as a file.
02

Study summary

The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.

03

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast
  • Radiologic or pathologic evidence that the cancer is or locally advanced (a T4 tumor and stage IIIB/IIIC disease) and not curable by local measures, such as radiation or surgery
  • Positive status for human epidermal growth factor receptor 2
  • as per guidelines
  • performance status of 70 to 100
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine
  • Common Terminology Criteria Grade 2 or greater neuropathy
  • Inadequate hematologic, hepatic, or renal function
  • Known prior severe reactions to agents containing Cremophor® EL or known hypersensitivity or prior intolerance to fluoropyrimidine
  • Known or suspected dihydropyrimidine dehydrogenase deficiency
  • More than 3 prior chemotherapy regimens in the setting
  • Prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg

    Dose Level 1

    Drug: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg

  • Experimental
    Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg

    Dose Level 2

    Drug: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg

  • Experimental
    Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg

    Dose Level 3

    Drug: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg

  • Experimental
    Ixabepilone + Lapatinib + Capecitabine

    Triplet Combination

    Drug: Ixabepilone + Lapatinib + Capecitabine

Interventions

  • DrugIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg

    Drug page: Ixabepilone

    Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.

  • DrugIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg

    Drug page: Ixabepilone

    Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.

  • DrugIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg

    Drug page: Ixabepilone

    Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.

  • DrugIxabepilone + Lapatinib + Capecitabine

    Drug pages: Ixabepilone · Lapatinib · Capecitabine

    Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Ixabepilone When Administered With Lapatinib

    The MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a dose-limiting toxicity (DLT), with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.

    Time frame: Days 1 through 21

  2. MTD and RP2D of Ixabepilone When Administered With Lapatinib Plus Capecitabine

    MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a DLT, with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.

    Time frame: Days 1 through 21

Secondary outcomes

  1. Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Treatment-related AEs, Treatment-related AEs (Grade 3 or 4), Peripheral Neuropathy (PN), PN (Grade 3 or 4)

    AE=Any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, important, a congenital anomaly/birth defect; or requires or prolongs existing hospitalization. Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment. Common Terminology Criteria (CTC) Grade 3=severe; Grade 4=life-threatening or disabling.

    Time frame: Baseline to Day 21, continuously

  2. Number of Participants With DLT

    DLT=Any of the following events, attributable to study drug and occurring within 21 days after ixabepilone administration: Grade 3 or 4 nausea, vomiting, or diarrhea despite the use of adequate medical intervention; other Grade 3 or greater nonhematologic toxicity requiring removal from study drug; recovery from study drug-related toxicity that delayed scheduled retreatment for longer than 3 weeks; Grade 4 neutropenia for 5 or more consecutive days or Grade 3 or 4 neutropenia of any duration with sepsis or fever; thrombocytopenia or bleeding requiring platelet transfusion.

    Time frame: Baseline to Day 21, continuously

  3. Number of Participants With Abnormalities in Hematology Laboratory Results by Worst CTC Grade

    CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. WBC (c/L): Grade (Gr)1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L; ANC (c/uL): Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L; Platelet count (c/uL): Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0\*10\^9/L; Hemoglobin (g/dL): Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL.

    Time frame: Baseline and weekly from Days 1 to 21 (Cycle 1)

  4. Number of Participants With Abnormalities in Serum Chemistry Laboratory Results by Worst CTC Grade

    CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. ALT(U/L) Gr 1:\>ULN-2.5\*ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; AST(U/L) Gr 1:\>ULN-2.5\* ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; ALP(U/L)Gr 1:\>ULN-2.5\*ULN, Gr 2:\>2.5-5.0\*ULN, Gr 3:\>5.0-20.0\*ULN, Gr 4:\>20.0\*ULN; Creatinine (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-6.0\*ULN, Gr 4:\>6.0\*ULN; Total bilirubin (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-10.0\*ULN, Gr 4:\>10.0\*ULN

    Time frame: At baseline and within 72 hours of Day 1 of 21-day cycle

  5. Maximum Concentration of Ixabepilone

    Time frame: Day 1 of 21-day cycle

  6. Area Under the Concentration-time Curve From 0 to Infinity (AUC[INF]) and AUC From 0 to Last Quantifiable Concentration (AUC[O-T] of Ixabepilone

    Time frame: Day 1 of 21-day cycle

  7. Terminal Half-life of Ixabepilone

    Time frame: Day 1 of 21-day cycle

  8. Time to Peak Concentration of Ixabepilone

    Time frame: Day 1 of 21-day cycle

  9. Volume of Distribution at Steady State of Ixabepilone

    Time frame: Day 1 of 21-day cycle

  10. Overall Tumor Response By Number of Participants

    Target lesion criteria: Complete Response(CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial Response (PR)=A 30% or greater decrease in the sum of longest diameter(LD) of all lesions in reference to the baseline sum LD. Stable Disease (SD)=Insufficient increase to qualify for Progressive Disease (PD) and insufficient shrinkage to qualify for PR; PD=A 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.

    Time frame: Baseline and Day 21 (21-day cycle)

  11. Duration of Response of Combination Treatment With Ixabepilone Plus Lapatinib

    Duration of response is measured from the time in months that measurement criteria are first met for PR or CR, whichever is recorded first, until the date of documented PD or death. Participants who neither relapse nor die will be censored on the date of their last tumor assessment.

    Time frame: First occurrence of PR or CR to PD or Death (no average, as no data available)

07

Results

Posted May 3, 2011

Participant flow

Time Period 1: Dose Level 1
Participant flow — Time Period 1: Dose Level 1
MilestoneIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone+ Lapatinib + Capecitabine
Started6000
Completed0000
Not completed6000
Withdrew: Disease progression2000
Withdrew: Physician decision1000
Withdrew: Adverse event3000
Time Period 2: Dose Level 2
Participant flow — Time Period 2: Dose Level 2
MilestoneIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone+ Lapatinib + Capecitabine
Started0300
Completed0000
Not completed0300
Withdrew: Adverse event0200
Withdrew: Progressive disease0100
Time Period 3: Dose Level 3
Participant flow — Time Period 3: Dose Level 3
MilestoneIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone+ Lapatinib + Capecitabine
Started0010
Completed0000
Not completed0010
Withdrew: Progressive disease0010
Time Period 4: Triplet Combination
Participant flow — Time Period 4: Triplet Combination
MilestoneIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone+ Lapatinib + Capecitabine
Started0000
Completed0000
Not completed0000

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Ixabepilone When Administered With Lapatinib

The MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a dose-limiting toxicity (DLT), with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.

Time frame:
Days 1 through 21

No measurements were reported for this outcome.

SecondaryNumber of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Treatment-related AEs, Treatment-related AEs (Grade 3 or 4), Peripheral Neuropathy (PN), PN (Grade 3 or 4)

AE=Any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, important, a congenital anomaly/birth defect; or requires or prolongs existing hospitalization. Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment. Common Terminology Criteria (CTC) Grade 3=severe; Grade 4=life-threatening or disabling.

Time frame:
Baseline to Day 21, continuously
Reported as:
Number · Participants
Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Treatment-related AEs, Treatment-related AEs (Grade 3 or 4), Peripheral Neuropathy (PN), PN (Grade 3 or 4)
ParticipantsIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Death300—
SAEs201—
AEs leading to discontinuation320—
Treatment-related AEs631—
Treatment-related AEs (Grade 3 or 4)331—
PN420—
PN (Grade 3 or 4)110—
SecondaryNumber of Participants With DLT

DLT=Any of the following events, attributable to study drug and occurring within 21 days after ixabepilone administration: Grade 3 or 4 nausea, vomiting, or diarrhea despite the use of adequate medical intervention; other Grade 3 or greater nonhematologic toxicity requiring removal from study drug; recovery from study drug-related toxicity that delayed scheduled retreatment for longer than 3 weeks; Grade 4 neutropenia for 5 or more consecutive days or Grade 3 or 4 neutropenia of any duration with sepsis or fever; thrombocytopenia or bleeding requiring platelet transfusion.

Time frame:
Baseline to Day 21, continuously
Reported as:
Number · Participants
Number of Participants With DLT
ParticipantsIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Number of Participants With DLT100—
SecondaryNumber of Participants With Abnormalities in Hematology Laboratory Results by Worst CTC Grade

CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. WBC (c/L): Grade (Gr)1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L; ANC (c/uL): Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L; Platelet count (c/uL): Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0\*10\^9/L; Hemoglobin (g/dL): Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL.

Time frame:
Baseline and weekly from Days 1 to 21 (Cycle 1)
Reported as:
Number · Participants
Number of Participants With Abnormalities in Hematology Laboratory Results by Worst CTC Grade
ParticipantsIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
White blood cell count (WBC) (Grade 1)101—
WBC (Grade 2)100—
WBC (Grade 3)230—
WBC (Grade 4)100—
Absolute neutrophil count (ANC) (Grade 1)000—
ANC (Grade 2)100—
ANC (Grade 3)210—
ANC (Grade 4)220—
Platelet count (Grade 1)112—
Platelet count (Grade 2)000—
Platelet count (Grade 3)000—
Platelet count (Grade 4)000—
Hemoglobin (Grade 1)336—
Hemoglobin (Grade 2)304—
Hemoglobin (Grade 3)000—
Hemoglobin (Grade 4)000—
SecondaryNumber of Participants With Abnormalities in Serum Chemistry Laboratory Results by Worst CTC Grade

CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. ALT(U/L) Gr 1:\>ULN-2.5\*ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; AST(U/L) Gr 1:\>ULN-2.5\* ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; ALP(U/L)Gr 1:\>ULN-2.5\*ULN, Gr 2:\>2.5-5.0\*ULN, Gr 3:\>5.0-20.0\*ULN, Gr 4:\>20.0\*ULN; Creatinine (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-6.0\*ULN, Gr 4:\>6.0\*ULN; Total bilirubin (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-10.0\*ULN, Gr 4:\>10.0\*ULN

Time frame:
At baseline and within 72 hours of Day 1 of 21-day cycle
Reported as:
Number · Participants
Number of Participants With Abnormalities in Serum Chemistry Laboratory Results by Worst CTC Grade
ParticipantsIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Alanine aminotransferase (ALT) (Grade 1)100—
ALT (Grade 2)000—
ALT (Grade 3)000—
ALT (Grade 4)000—
Aspartate aminotransferase (AST) (Grade 1)100—
AST (Grade 2)000—
AST (Grade 3)000—
AST (Grade 4)000—
Alkaline phosphatase (ALP) (Grade 1)300—
ALP (Grade 2)000—
ALP (Grade 3)000—
ALP (Grade 4)000—
Creatinine (Grade 1)000—
Creatinine (Grade 2)000—
Creatinine (Grade 3)000—
Creatinine (Grade 4)000—
Total bilirubin (Grade 1)000—
Total bilirubin (Grade 2)000—
Total bilirubin (Grade 3)000—
Total bilirubin (Grade 4)000—
SecondaryMaximum Concentration of Ixabepilone
Time frame:
Day 1 of 21-day cycle
Reported as:
Geometric mean · ng/mL
Maximum Concentration of Ixabepilone
ng/mLIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Maximum Concentration of Ixabepilone200.6 ± 78.4109.2 ± 1.1133.4 (133.4 to 133.4)—
SecondaryArea Under the Concentration-time Curve From 0 to Infinity (AUC[INF]) and AUC From 0 to Last Quantifiable Concentration (AUC[O-T] of Ixabepilone
Time frame:
Day 1 of 21-day cycle
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve From 0 to Infinity (AUC[INF]) and AUC From 0 to Last Quantifiable Concentration (AUC[O-T] of Ixabepilone
ng*h/mLIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
AUC(INF)2212.9 ± 1030.42427.0 ± 225.51610.7—
AUC(O-T)1851.8 ± 880.52082.0 ± 133.61284.2—
SecondaryTerminal Half-life of Ixabepilone
Time frame:
Day 1 of 21-day cycle
Reported as:
Mean · Hours
Terminal Half-life of Ixabepilone
HoursIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Terminal Half-life of Ixabepilone51.6 ± 13.263.1 ± 10.433.1—
SecondaryTime to Peak Concentration of Ixabepilone
Time frame:
Day 1 of 21-day cycle
Reported as:
Median · Hours
Time to Peak Concentration of Ixabepilone
HoursIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Time to Peak Concentration of Ixabepilone3.0 (2.0 to 3.4)3.0 (3.0 to 3.0)2.9 (2.9 to 2.9)—
SecondaryVolume of Distribution at Steady State of Ixabepilone
Time frame:
Day 1 of 21-day cycle
Reported as:
Mean · Liters
Volume of Distribution at Steady State of Ixabepilone
LitersIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
Volume of Distribution at Steady State of Ixabepilone1484.3 ± 438.51780.8 ± 237.91915.8—
PrimaryMTD and RP2D of Ixabepilone When Administered With Lapatinib Plus Capecitabine

MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a DLT, with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.

Time frame:
Days 1 through 21

No measurements were reported for this outcome.

SecondaryOverall Tumor Response By Number of Participants

Target lesion criteria: Complete Response(CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial Response (PR)=A 30% or greater decrease in the sum of longest diameter(LD) of all lesions in reference to the baseline sum LD. Stable Disease (SD)=Insufficient increase to qualify for Progressive Disease (PD) and insufficient shrinkage to qualify for PR; PD=A 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.

Time frame:
Baseline and Day 21 (21-day cycle)
Reported as:
Number · Participants
Overall Tumor Response By Number of Participants
ParticipantsIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone + Lapatinib + Capecitabine
CR3 ± 12.22 ± 2.10—
PR000—
SD311—
PD000—
SecondaryDuration of Response of Combination Treatment With Ixabepilone Plus Lapatinib

Duration of response is measured from the time in months that measurement criteria are first met for PR or CR, whichever is recorded first, until the date of documented PD or death. Participants who neither relapse nor die will be censored on the date of their last tumor assessment.

Time frame:
First occurrence of PR or CR to PD or Death (no average, as no data available)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline to Day 21, continuously. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d—2/6 (33.3%)6/6 (100%)
Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d—0/3 (0%)3/3 (100%)
Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d—1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d
NAUSEAGastrointestinal disorders0/60/31/1
VOMITINGGastrointestinal disorders0/60/31/1
DIARRHOEAGastrointestinal disorders0/60/31/1
URINARY TRACT INFECTIONInfections and infestations0/60/31/1
DEHYDRATIONMetabolism and nutrition disorders0/60/31/1
CHEST PAINGeneral disorders0/60/31/1
DEVICE RELATED INFECTIONInfections and infestations1/60/30/1
HYPOKALAEMIAMetabolism and nutrition disorders1/60/30/1
DECREASED APPETITEMetabolism and nutrition disorders1/60/30/1
ANAEMIABlood and lymphatic system disorders1/60/30/1
Most frequent other events
Showing 10 of 87
Most frequent other events
EventIxabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/dIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/dIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d
HAEMOGLOBIN DECREASEDInvestigations1/60/31/1
INSOMNIAPsychiatric disorders2/60/31/1
LETHARGYNervous system disorders1/60/31/1
NAUSEAGastrointestinal disorders5/61/31/1
VOMITINGGastrointestinal disorders3/60/31/1
DIARRHOEAGastrointestinal disorders5/63/31/1
CONSTIPATIONGastrointestinal disorders2/60/31/1
ABDOMINAL PAINGastrointestinal disorders1/60/31/1
URINARY TRACT INFECTIONInfections and infestations0/60/31/1
MICTURITION URGENCYRenal and urinary disorders0/60/31/1

Baseline characteristics

Age, Customized
Age, Customized(participants)Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone + Lapatinib + CapecitabineTotal
Younger than 50 years110—2
50 years and older to younger than 65 years421—7
65 years and older100—1
Gender
Gender(participants)Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone + Lapatinib + CapecitabineTotal
Female631—10
Male000—0
Race (NIH/OMB)
Race (NIH/OMB)(participants)Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mgIxabepilone, 32 mg/m^2 + Lapatinib, 1250 mgIxabepilone, 40 mg/m^2 + Lapatinib, 1250 mgIxabepilone + Lapatinib + CapecitabineTotal
American Indian or Alaska Native000—0
Asian100—1
Native Hawaiian or Other Pacific Islander000—0
Black or African American000—0
White531—9
More than one race000—0
Unknown or Not Reported000—0
08

Study locations

3 sites
  • The Cancer Institute Of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Local Institution
    Brisbane, Queensland 4101, Australia
  • Local Institution
    Modena, 41100, Italy
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 12, 2008
Start
Jun 2008
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
May 3, 2011
Last update
Mar 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00634088
Lead sponsor
R-Pharm
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 12, 2008
Start date
Jun 2008
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
May 3, 2011
Last update
Mar 10, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixabepilone · Lapatinib · Capecitabine

Start the discussion